Skip to content
AgingNexus
☰ Menu

Evidence brief · intervention

Rapamycin / mTOR inhibition

Synthesized from 10 indexed sources · 2026-09-10 MST · preview (no AI key)
Preview synthesis (deterministic, no AI key configured). Set a provider key to generate the full brief.

Synthesis (preview — no live AI key for the active provider):

Across the retrieved literature, senescent-cell burden and chronic inflammation recur as central, interacting drivers, with intervention studies reporting functional gains in model organisms. Key works: [1][2][3][4][5].

Set the active provider's API key to generate full model-written analysis.

Sources

  1. [1] Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy
  2. [2] Upstream and downstream of mTOR
  3. [3] Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
  4. [4] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
  5. [5] Targeting cancer stem cell pathways for cancer therapy
  6. [6] The Intersection Between Aging and Cardiovascular Disease
  7. [7] PI3K/AKT signaling pathway and cancer: an updated review
  8. [8] Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster
  9. [9] A Novel Human Cellular System for Studying Normal Aging and for Anti‐Aging Discovery
  10. [10] Loss-of-Function (G603R) Lrp10 Fails to Downregulate mRNA of Pathologic α-Synuclein and Causes Neurodegeneration of Substantia Nigra Dopaminergic Cells in Parkinson's Disease Knockin Mice.
All Rapamycin / mTOR inhibition works → Intervention dossier →